-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Benzinga·12/19/2024 12:50:45
Listen to the news
Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $11 price target.